Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

ADMA Biologics Inc

Healthcare US ADMA

15.83USD
0.02(0.13%)

Last update at 2026-03-10T20:04:00Z

Day Range

15.6216.18
LowHigh

52 Week Range

3.7323.64
LowHigh

Fundamentals

  • Previous Close 15.81
  • Market Cap4541.05M
  • Volume2152611
  • P/E Ratio71.15
  • Dividend Yield-%
  • EBITDA125.89M
  • Revenue TTM382.81M
  • Revenue Per Share TTM1.66
  • Gross Profit TTM 35.27M
  • Diluted EPS TTM0.27

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -65.90395M -71.64762M -75.74855M -48.27932M -65.74344M
Minority interest - - - - -
Net income -85.18332M -84.45288M -87.60509M -57.04537M -65.74344M
Selling general administrative 70.30M 55.19M 35.05M 25.91M 22.50M
Selling and marketing expenses - - - - -
Gross profit 35.27M 1.17M -19.07164M -10.15516M -25.20934M
Reconciled depreciation 7.11M 5.50M 3.94M 3.26M 3.45M
Ebit -39.36508M -58.37374M -64.91488M -41.42433M -60.22066M
Ebitda -39.23928M -57.87543M -64.03993M -40.00593M -56.77426M
Depreciation and amortization 0.13M 0.50M 0.87M 1.42M 3.45M
Non operating income net other -7.25950M -0.21704M 1.15M 2.14M 0.07M
Operating income -39.36508M -58.37374M -64.91488M -41.42433M -60.28894M
Other operating expenses 193.44M 139.32M 107.13M 70.77M 77.27M
Interest expense 19.28M 13.06M 11.99M 8.99M 5.52M
Tax provision - - - - -
Interest income 0.04M 0.03M 0.29M 0.80M 0.20M
Net interest income -19.23454M -13.02230M -11.69694M -8.19259M -5.32738M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 19.28M 12.81M 11.86M 8.77M 5.45M
Total revenue 154.08M 80.94M 42.22M 29.35M 16.99M
Total operating expenses 74.63M 59.55M 45.84M 31.27M 35.08M
Cost of revenue 118.81M 79.77M 61.29M 39.50M 42.19M
Total other income expense net -26.53887M -13.27388M -10.83367M -6.85499M -0.12712M
Discontinued operations - - - - -
Net income from continuing ops -65.90395M -71.64762M -75.74855M -48.27932M -65.74344M
Net income applicable to common shares -65.90395M -71.64762M -75.74855M -48.27932M -65.74344M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 329.18M 348.46M 276.25M 207.67M 127.09M
Intangible assets 0.50M 1.01M 1.73M 2.44M 3.16M
Earning assets - - - - -
Other current assets 5.33M 5.10M 4.34M 3.05M 2.53M
Total liab 193.98M 196.49M 135.08M 119.42M 100.90M
Total stockholder equity 135.21M 151.97M 141.17M 88.25M 26.19M
Deferred long term liab - - - - 2.26M
Other current liab 32.92M 24.99M 17.21M 8.37M 4.48M
Common stock 0.02M 0.02M 0.02M 0.01M 0.00593M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.00593M
Retained earnings -506.25600M -478.01667M -412.11272M -340.46510M -264.71656M
Other liab - 3.68M 2.37M 2173.58M 2.37M
Good will 3.53M 3.53M 3.53M 3.53M 3.53M
Other assets 0.00000M 4.77M 4.07M 6.37M 2.84M
Cash 51.35M 86.52M 51.09M 55.92M 26.75M
Cash and equivalents - - - - -
Total current liabilities 49.81M 39.27M 30.38M 19.95M 14.03M
Current deferred revenue 0.18M 0.14M 0.14M 0.14M 0.14M
Net debt 90.07M 67.92M 51.83M 41.75M 57.98M
Short term debt 1.04M 0.91M 0.59M 0.37M 0.23M
Short long term debt - - - - -
Short long term debt total 141.42M 154.44M 102.92M 97.67M 84.73M
Other stockholder equity 641.44M 629.97M 553.27M 428.70M 290.90M
Property plant equipment - 58.26M 50.94M 45852.28M 31.74M
Total current assets 257.01M 270.40M 208.73M 153.74M 85.82M
Long term investments - - - - -
Net tangible assets - 151.97M 141.17M 82275.80M 19.50M
Short term investments - - - - -
Net receivables 27.42M 15.51M 28.58M 13.24M 3.47M
Long term debt 130.59M 142.83M 94.87M 92.97M 68.29M
Inventory 172.91M 163.28M 124.72M 81.54M 53.06M
Accounts payable 15.66M 13.23M 12.43M 11.07M 9.17M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -5.72496M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.01M 0.00593M
Preferred stock total equity - - - - -
Retained earnings total equity - -478.01667M -412.11272M -340.46510M -264.71656M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.67M 4.77M 4.07M 2.11M 2.84M
Deferred long term asset charges - - - - -
Non current assets total 72.17M 78.06M 67.52M 53.93M 41.27M
Capital lease obligations 10.82M 11.61M 8.05M 4.70M 1.30M
Long term debt total - - - - 69.59M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -13.91117M -13.51126M -12.72468M -3.81184M -2.09560M
Change to liabilities 7.83M 9.92M 1.90M 3.89M 0.56M
Total cashflows from investing activities -13.91117M -13.51126M -12.72468M -3.81184M -2.09560M
Net borrowings 48.97M -0.03430M 13.52M 34.29M -0.03628M
Total cash from financing activities 108.85M 121.05M 143.90M 80.00M 42.92M
Change to operating activities 6.40M 5.49M 2.56M -0.04936M -0.16769M
Net income -65.90395M -71.64762M -75.74855M -48.27932M -65.74344M
Change in cash 35.43M -4.83203M 29.17M -0.00272M -21.85272M
Begin period cash flow 51.09M 55.92M 26.75M 26.75M 48.61M
End period cash flow 86.52M 51.09M 55.92M 26.75M 26.75M
Total cash from operating activities -59.50826M -112.36898M -102.00296M -76.19350M -62.67868M
Issuance of capital stock 64.65M 121.14M 131.20M 48.40M 42.94M
Depreciation 7.11M 5.50M 3.94M 3.26M 3.45M
Other cashflows from investing activities - - 0.00200M - -
Dividends paid - - - - -
Change to inventory -38.55596M -43.18849M -28.47086M -34.65013M -5.98799M
Change to account receivables 13.07M -15.33957M -9.76737M -2.07748M 2.49M
Sale purchase of stock 64.82M 121.14M 131.21M 48.47M 42.96M
Other cashflows from financing activities 144.24M -0.06160M 26.68M 61.64M 0.01M
Change to netincome 15.31M 3.71M 1.80M 2.86M 2.35M
Capital expenditures 13.91M 13.51M 12.73M 3.81M 2.10M
Change receivables 13.07M -15.33957M -9.76737M -2.07748M 2.49M
Cash flows other operating -0.63343M -3.06798M -0.70962M -2.23013M -0.74910M
Exchange rate changes - - - - -
Cash and cash equivalents changes 35.43M -4.83203M 29.17M -0.00272M -21.85272M
Change in working capital -18.28526M -51.68042M -33.78132M -33.50277M -3.68844M
Stock based compensation 5.21M 3.49M 2.86M 2.65M 2.22M
Other non cash items 12.35M 1.75M 1.64M 1.04M 0.96M
Free cash flow -73.41943M -125.88024M -114.72964M -80.00534M -64.77428M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ADMA
ADMA Biologics Inc		 0.02 0.13% 15.83 71.15 21.60 11.86 19.38 11.80 45.72
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc

465 State Route 17, Ramsey, NJ, United States, 07446

Key Executives

Name Title Year Born
Mr. Adam S. Grossman Co-Founder, Pres, CEO & Director 1977
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman 1948
Mr. Brian Lenz CPA, CPA Exec. VP, CFO & GM of ADMA BioCenters 1972
Ms. Kaitlin Kestenberg VP of Compliance, Project Management & Clinical Operations NA
Mr. Michael Goldstein Sr. Director & Gen. Counsel NA
Mr. Michael Least VP of Sales & Commercial Operations NA
Mr. Drew Pantello VP of Marketing & Corp. Devel. NA
Mr. Neal C. Fitzpatrick VP of Sales NA
Dr. Gene A. Wetzstein BCOP, Pharm.D. Exec. Director & Head of Scientific Engagement NA
Ms. Cyndi Tolman Sr. VP of Plasma Services NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.